The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors

DNA repair deficiency accumulates DNA damage and sensitizes tumor cells to PARP inhibitors (PARPi). Based on our observation that the BET inhibitor JQ1 increases levels of DNA damage, we evaluated the efficacy of JQ1 + the PARPi olaparib in preclinical models of pancreatic ductal adenocarcinoma (PDA...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	EBioMedicine 2019-06, Vol.44, p.419-430
Hauptverfasser:	Miller, Aubrey L., Fehling, Samuel C., Garcia, Patrick L., Gamblin, Tracy L., Council, Leona N., van Waardenburg, Robert C.A.M., Yang, Eddy S., Bradner, James E., Yoon, Karina J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acid Anhydride Hydrolases Animals Azepines - pharmacology BET bromodomain inhibitor (BETi) Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - genetics Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - pathology Cell Line, Tumor Disease Models, Animal DNA Breaks, Double-Stranded DNA double-strand break repair proteins DNA Repair - drug effects DNA repair and damage DNA Repair Enzymes - metabolism DNA-Binding Proteins - metabolism Drug Resistance, Neoplasm - genetics Female Histones - metabolism Humans Ku Autoantigen - metabolism Mice Pancreatic cancer Pancreatic Neoplasms Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology PARP inhibitor (PARPi) Patient-derived xenograft model Phthalazines - pharmacology Piperazines - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Research paper Triazoles - pharmacology Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!